Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans

Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with rifampin–streptomycin or rifampin–clarithromycin daily for 8 weeks recommended by World Health Organization (WHO). These options are lengthy with severe side effects. A new anti-tuberculosis drug, TB47, targeting QcrB in...

Full description

Bibliographic Details
Main Authors: Yamin Gao, H.M. Adnan Hameed, Yang Liu, Lingmin Guo, Cuiting Fang, Xirong Tian, Zhiyong Liu, Shuai Wang, Zhili Lu, Md Mahmudul Islam, Tianyu Zhang
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Mycobacterium ulcerans
Buruli ulcer
Electron transport chain
QcrB
Chemotherapy
TB47
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383520307966

Internet

http://www.sciencedirect.com/science/article/pii/S2211383520307966

Similar Items